Correspondence 0001493152-23-010063 from CytoMed Therapeutics Ltd (GDTC)

CytoMed Therapeutics Ltd
Date: March 31, 2023 · CIK: 0001873093 · Accession: 0001493152-23-010063

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-268456

Date

November 18, 2022

Author

Director

Form

CORRESP

Company

CytoMed Therapeutics Ltd

Letter

VIA EDGAR Division of Corporation Finance, Office of Life Sciences Attention: Tracie Mariner Re: CytoMed Therapeutics Limited Registration Statement on Form F-1 Originally Filed November 18, 2022 File No. 333-268456

Dear Ms. Mariner:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, CytoMed Therapeutics Limited (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. on Friday, March 31, 2023, or as soon as thereafter practicable (the “Effective Time”). The Company hereby grants to each of Richard I. Anslow, Esq., Lijia Sanchez, Esq. and Kristina R. Brown, Esq. the authority to communicate to the staff of the U.S. Securities and Exchange Commission one or more requests for any potential deferral of the Effective Time.

Very
truly yours,
/s/
CHOO Chee Kong

Show Raw Text

CORRESP
1
filename1.htm

CytoMed
Therapeutics Limited

1
Commonwealth Lane #08-22

Singapore
149544

March
31, 2023

VIA
EDGAR

U.S.
SECURITIES AND EXCHANGE COMMISSION

Division
of Corporation Finance, Office of Life Sciences

100
F Street, N.E.

Washington,
DC 20549

Attention:
Tracie Mariner

    Re:
    CytoMed
    Therapeutics Limited

Registration
Statement on Form F-1

Originally
Filed November 18, 2022

File
No. 333-268456

Dear
Ms. Mariner:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, CytoMed Therapeutics Limited (the “Company”) hereby requests
acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m. on Friday,
March 31, 2023, or as soon as thereafter practicable (the “Effective Time”). The Company hereby grants to each of
Richard I. Anslow, Esq., Lijia Sanchez, Esq. and Kristina R. Brown, Esq. the authority to communicate to the staff of the U.S. Securities
and Exchange Commission one or more requests for any potential deferral of the Effective Time.

    Very
    truly yours,

    /s/
    CHOO Chee Kong

    CHOO
    Chee Kong

    Director
    and Chairman

SecProbe.io